References
- Chamberlain R, Canes D, Brown K, Saltz L, Jarnagin W, Fong Y, et al. Hepatic neuroendocrine metastases: does intervention alter outcome? J Am Coll Surg 2000; 190: 432-45. http://dx.doi.org/10.1016/S1072-7515(00)00222-2
- Tomassetti P, Migliori M, Lalli S, Campana D, Tomassetti V, Corinaldesi R. Epidemiology, clinical features and diagnosis of gastroenteropancreatic endocrine tumors. Ann Oncol 2001; 12 (Suppl 2): S95-9.
- Madoff D, Gupta S, Ahrar K, Murthy R, Yao JC. Update on the management of neuroendocrine hepatic metastases. J Vasc Interv Radiol 2006; 17: 1235-49; quiz 1250. 10.1097/01.RVI.0000232177.57950.71
- Mayo S, De Jong M, Bloomston M, Pulitano C, Clary B, Reddy S, et al. Surgery versus intra-arterial therapy for neuroendocrine liver metastases: a multicenter international analysis. Ann Surg Oncol 2011; 18: 3657-65. 10.1245/s10434-010-1343-2
- Arrese D, McNally ME, Chokshi R, Feria-Arias E, Schmidt C, Klemanski D, et al. Extrahepatic disease should not preclude transarterial chemoembolization for metastatic neuroendocrine carcinoma. Ann Surg Oncol 2013; 20: 1114-20. 10.1245/s10434-012-2786-4
- Ruutiainen A, Soulen M, Tuite C, Clark T, Mondschein J, Stavropoulos S, et al. Chemoembolization and bland embolization of neuroendocrine tumor metastases to the liver. J Vasc Interv Radiol 2007; 18: 847-55. 10.1016/j. jvir.2007.04.018
- Ho A, Picus J, Darcy MD, Tan B, Gould JE, Pilgram TK, et al. Long-term outcome after chemoembolization and embolization of hepatic metastatic lesions from neuroendocrine tumors. AJR Am J Roentgenol 2007; 188: 1201-7. 10.2214/AJR.06.0933
- Hur S, Chung J, Kim H, Oh D, Lee S, Bang Y, et al. Survival outcomes and prognostic factors of transcatheter arterial chemoembolization for hepatic neuroendocrine metastases. J Vasc Interv Radiol 2013; 24: 947-56. 10.1016/j.jvir.2013.02.030
- Devcic Z, Rosenberg J, Braat A, Techasith T, Banerjee A, Sze D, et al. The efficacy of hepatic 90Y resin radioembolization for metastastic neuroendocrine tumors: a meta-analysis. J Nuc Med 2014; 55: 1404-10. 10.2967/ jnumed.113.135855
- Memon K, Lewandowski R, Mulcahy M, Riaz A, Ryu R, Sato K, et al. Radioembolization for neuroendocrine liver metastases: safety, imaging and long-term outcomes. Int J Radiat Oncol Biol Phys 2012; 83: 887-94. 10.1016/j.ijrobp.2011.07.041
- de Baere T, Deschamps F, Tselikas L, Ducreux M, Planchard D, Pearson E, et al. GEP-NETS update: Interventional radiology: role in the treatment of liver metastases from GEP-NETs. Eur J Endocrinol 2015; 172: R151-66. 10.1530/EJE-14-0630
- Lammer J, Malagari K, Vogl T, Pilleul F, Denys A, Watkinson A, et al; PRECISION V Investigators. Prospective randomized study of doxorubicineluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION study. Cardiovasc Intervent Radiol 2010; 33: 41-45. 10.1007/s00270-009-9711-7
- Dekervel J, van Malenstein H, Vandecaveye V, Nevens F, van Pelt J, Heye S, et al. Transcatheter arterial chemoembolization with doxorubicin-eluting superabsorbent polymer microspheres in the treatment of hepatocellular carcinoma: midterm follow-up. J Vasc Interv Radiol 2014; 25: 248-55. 10.1016/j.jvir.2013.10.017
- Huppert P, Wenzel T, Wietholtz H. Transcatheter arterial chemoembolization (TACE) of colorectal cancer liver metastases by irinotecan-eluting microspheres in a salvage patient population. Cardiovasc Intervent Radiol 2014; 37: 154-64. 10.1007/s00270-013-0632-0
- Aliberti C, Fiorentini G, Muzzio PC, Pomerri F, Tilli M, Dallara S, et al. Transarterial chemoembolization of metastatic colorectal carcinoma to the liver adopting DC Bead®, drug-eluting bead loaded with irinotecan: results of a phase II clinical study. Anticancer Res 2011; 31: 4581-7.
- Fiorentini G, Aliberti C, Turrisi G, Del Conte A, Rossi S, Benea G, et al. Intraarterial hepatic chemoembolization of liver metastases from colorectal cancer adopting irinotecan-eluting beads: results of a phase II clinical study. In Vivo 2007; 21: 1085-91.
- van Malenstein H, Maleux G, Vandecaveye V, Heye S, Laleman W, van Pelt J, et al. A randomized phase II study of drug-eluting beads versus transarterial chemoembolization for unresectable hepatocellular carcinoma. Onkologie 2011; 34: 368-76. 10.1159/000329602
- Varela M, Real M, Burrel M, Forner A, Sala M, Brunet M, et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol 2007; 46: 474-81. 10.1016/j.jhep.2006.10.020
- Vogl T, Lammer J, Lencioni R, Malagari K, Watkinson A, Pilleul F, et al. Liver, gastrointestinal and cardiac toxicity in intermediate hepatocellular carcinoma with PRECISION TACE with drug-eluting beads: results from the PRECISION V randomized trial. AJR Am J Roentgenol 2011; 197: W562-70. 10.2214/AJR.10.4379
- Bhagat N, Reyes D, Lin M, Kamel I, Pawlik T, Frangakis C, et al. Phase II study of chemoembolization with drug-eluting beads in patients with hepatic neuroendocrine metastases: high incidence of biliary injury. Cardiovasc Intervent Radiol 2013: 36: 449-59. 10.1016/j.jvir.2012.08.028
- Guiu B, Descamps F, Aho S, Munck F, Dromain C, Boige V, et al. Liver/biliary injuries following chemoembolization of endocrine tumours and hepatocellular carcinoma: lipiodol versus drug-eluting beads. J Hepatol 2012: 56: 609-617. 10.1016/j.jhep.2011.09.012
- Joskin J, de Baere T, Auperin A, Tselikas L, Guiu B, Farouil G, et al. Predisposing factors of liver necrosis after transcatheter arterial chemoembolization in liver metastases from neuroendocrine tumor. Cardiovasc Intervent Radiol 2015; 38: 372-380. 10.1016/j.jhep.2011.09.012
- De Baere T, Deschamps F, Teriitheau C, Rao P, Conengrapht K, Schlumberger M, et al. Transarterial chemoembolization of liver metastases from well differentiated gastroenteropancreatic endocrine tumors with doxorubicineluting beads: preliminary results. J Vasc Interv Radiol 2008; 19: 855-61. 10.1016/j.jvir.2008.01.030
- Sakamoto I, Iwanaga S, Nagaoki K, Matsuoka Y, Ashizawa K, Uetani M, et al. Intrahepatic biloma formation (bile duct necrosis) after transcatheter arterial chemoembolization. AJR Am J Roentgenol 2003; 181: 79-87. 10.2214/ajr.181.1.1810079
- Gaur S, Friese J, Sadow C, Ayyagari R, Binkert C, Schenker M, et al. Hepatic arterial chemoembolization using drug-eluting beads in gastrointestinal neuroendocrine tumor metastatic to the liver. Cardiovasc Intervent Radiol 2011; 34: 566-72. 10.1007/s00270-011-0122-1
- Loewe C, Schindl M, Cejna M, Niederle B, Lammer J, Thurnher S. Permanent transarterial embolization of neuroendocrine metastases of th eliver using cyanoacrylate and lipiodol: assessment of mid-and long-term results. AJR Am J Roentgenol 2003; 180: 1379-84. 10.2214/ajr.180.5.1801379
- Bilbao J, de Luis E, García de Jalón JA, de Martino A, Lozano MD, de la Cuesta AM, et al. Comparative study of four different spherical embolic particles in an animal model: a morphologic and histologic evaluation. J Vasc Interv Radiol 2008; 19: 1625-38. 10.1016/j.jvir.2008.07.014
- De Luis E, Bilbao JI, de Ciércoles JA, Martínez-Cuesta A, de Martino Rodríguez A, Lozano MD. In vivo evaluation of a new embolic spherical particle (HepaSphere) in a kidney animal model. Cardiovasc Intervent Radiol 2008; 31: 367-76. 10.1007/s00270-007-9240-1